Amgen Inc (AMGN) operating KPIs
AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 17/3039% above fair value
$466.01+5.28 (+1.15%)
Close on Oct 30, 2026Market cap $251.94BP/E 28.9Yield 2.07%
Amgen deferred Tax Assets (DTA) — Total Gross DTA ($M) ($M)
Form 10-K Income Taxes Note (XBRL)
Latest, FY2025
6,923
Period ended Dec 31, 2025
Change on a year earlier
+15.5%
5,995 in FY2024
History
11 years
Since FY2015
Sources
9
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Deferred Tax Assets (DTA) — Total Gross DTA ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 6,923 | +15.5% | Form 10-K (filed 2026-02-13) ↗ |
| FY2024 | Dec 31, 2024 | 5,995 | +8.8% | Form 10-K (filed 2026-02-13) ↗ |
| FY2023 | Dec 31, 2023 | 5,511 | +55.8% | Form 10-K (filed 2025-02-14) ↗ |
| FY2022 | Dec 31, 2022 | 3,537 | +51.7% | Form 10-K (filed 2024-02-14) ↗ |
| FY2021 | Dec 31, 2021 | 2,331 | +23.2% | Form 10-K (filed 2023-02-09) ↗ |
| FY2020 | Dec 31, 2020 | 1,892 | +5.9% | Form 10-K (filed 2022-02-16) ↗ |
| FY2019 | Dec 31, 2019 | 1,787 | +5.6% | Form 10-K (filed 2021-02-09) ↗ |
| FY2018 | Dec 31, 2018 | 1,692 | +7.0% | Form 10-K (filed 2019-02-13) ↗ |
| FY2017 | Dec 31, 2017 | 1,582 | -11.6% | Form 10-K (filed 2019-02-13) ↗ |
| FY2016 | Dec 31, 2016 | 1,789 | -11.0% | Form 10-K (filed 2018-02-13) ↗ |
| FY2015 | Dec 31, 2015 | 2,009 | – | Form 10-K (filed 2017-02-14) ↗ |
Breakdown
What makes up deferred tax assets (dta) — total gross dta ($m)
- DTA — Capitalized R&D Expenses ($M)1,655 · FY2025
- DTA — Net Operating Loss (NOL) & Tax Credit Carryforwards ($M)1,368 · FY2025
- DTA — Accrued Liabilities & Sales Deductions ($M)890 · FY2025
- DTA — Employee Compensation & Stock-Based Compensation ($M)138 · FY2025
- DTA — Other Expenses Not Currently Deductible ($M)218 · FY2025
- DTA — Equity Investments ($M)0 · FY2025
- DTA — Other Deferred Tax Assets ($M)349 · FY2025
- DTA Valuation Allowance ($M)1,299 · FY2025
- Total Deferred Tax Assets Net of Valuation Allowance ($M)5,624 · FY2025
Cite this data
StockData. (2026). Amgen Deferred Tax Assets (DTA) — Total Gross DTA ($M) ($M), annual FY2015–FY2025 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/dta_gross
See every metric in the Amgen KPI table. Data updated Oct 28, 2026.